Cogent Biosciences(COGT)
Focus: Cogent Biosciences is a public biotech company focused on cellular immunotherapies for oncology and neurology, with a pipeline of 17 active clinical programs spanning Phase 1 to Phase 3 development.
Profile data last refreshed 17m ago · AI intelligence enriched 2mo ago
Funding Stage
PUBLIC
Open Jobs
21+5 this month
Growing — net +5 jobs in 30d
13 jobs added vs 8 removed. Steady team buildout.
Should You Work at Cogent Biosciences?
AI assessmentCogent offers high-risk/high-reward exposure to innovative immunotherapy technology, but deteriorating cash position and early-stage pipeline require careful assessment of personal risk tolerance.
Why Work Here
- Accelerating clinical momentum: recent NDA submission for bezuclastinib in Advanced Systemic Mastocytosis and Phase 3 data expected for CGT9486 in GIST signal near-term value creation
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
ACTR T Cell Product
B Cell LymphomasClinical Trials (1)
NCT02840110Long-Term Follow-Up Study of Subjects Treated With ACTR T Cell Product
N/AHelp build intelligence for Cogent Biosciences
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.